OakChart

Biodexa Pharmaceuticals Plc ADR

BDRXHealthcare·Biotechnology·United Kingdom·Nano·NASD·Nov 11 • 3:59 PM ET

2.40-0.06 (-2.44%)
2026-11-12 00:30 CET
Market cap
1.29 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-5.93 USD m
Free cash flow, TTM
-9.23 USD m
EPS diluted, TTM
-53.56
P/E
-
Compare

Price

BDRX against its 20, 50 and 200-day averages
2050200earnings
0.0050.00100.00150.008.9M17.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BDRXclose 2.4020-day 3.1550-day 4.71200-day 21.982.40

99.3% under the 52-week high of 357.60 on 8 Dec 2025. 52-week low 2.28 on 6 Nov 2026. Last 15 sessions, 85.5% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Profile

BDRX
52-week range, 0% of the way up
2.28357.6

Biodexa Pharmaceuticals Plc is a drug delivery technology company. The firm is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. Its proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Employees11
IPODec 07, 2015
Beta1.28
ATR, 14d0.49
Rel volume0.03
Inst own0.66%

Snapshot

6 groups

Valuation

Index-
Market Cap1.25M
Enterprise Value-3.04M
Income-5.93M
Sales0.00M
Book/sh0.00
Cash/sh8.25
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees11
IPODec 07, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1889.76
P/C0.29
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio2.41
Current Ratio2.41
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-53.56
EPS next Y0.00
EPS next Q0.00
EPS this Y100.00%
EPS next Y-
EPS next 5Y-
EPS past 3/5Y95.64% 89.65%
Sales past 3/5Y- -
EPS Y/Y TTM97.97%
Sales Y/Y TTM-
EPS Q/Q100.00%
Sales Q/Q-
EarningsSep 11 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own-
Insider Trans-
Inst Own0.66%
Inst Trans-
ROA-31.88%
ROE-41.72%
ROIC-46.48%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-23.78%
SMA50-49.08%
SMA200-89.08%
Trades-

Technical

Shs Outstand932.64M
Shs Float-
Short Float-
Short Ratio0.01
Short Interest0.01M
52W High357.60 -99.33%
52W Low2.28 5.26%
Volatility12.15% 14.53%
ATR (14)0.49
RSI (14)32.53
Beta1.28
Rel Volume0.03
Avg Volume611.17K
Volume19,920

Performance

Perf Week-10.78%
Perf Month-14.33%
Perf Quarter-80.77%
Perf Half Y-91.92%
Perf YTD-97.36%
Perf Year-98.94%
Perf 3Y-99.99%
Perf 5Y-100.00%
Perf 10Y-100.00%
Recom1.00
Target Price72.00
Prev Close2.46
Price2.40
Change %-2.44%

Analyst ratings

latest 1 of 1
DateActionAnalystRating changeTargetImplied
Feb 08, 2024InitiatedLLadenburg ThalmannBuy$8+233.3%

Peers

Mkt cap
TickerCompanyMkt cap
KZIAKazia Therapeutics Limited ADR84.92M
NTHINeOnc Technologies Holdings Inc130.41M
MBRXMoleculin Biotech Inc8.50M
NCNANuCana plc ADR4.05M
PPBTPurple Biotech Ltd ADR2.41M
LTRNLantern Pharma Inc7.19M
CDTCDT Equity Inc0.52M
SCNIScinai Immunotherapeutics Ltd ADR0.69M
QNRXQuoin Pharmaceuticals Ltd ADR18.05M
XTLBX.T.L. Biopharmaceuticals Ltd ADR7.44M

News

latest 14 of 200
  • Biodexa provides R&D Update (GlobeNewswire)
  • Biodexa Reaches 100-Patient Enrollment Milestone in Phase 3 Serenta Trial as Key Analysis Timeline Accelerates (InvestorsHub) -8.61%
  • Biodexa announces another Serenta milestone with 100 patients enrolled in its registrational Phase 3 trial in FAP (GlobeNewswire)
  • The Longview: Fireside Chat with Biodexa CEO Stephen Stamp (ACCESSWIRE)
  • Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds (GlobeNewswire) +18.75%
  • Interim results for the six months ended June 30, 2026 (GlobeNewswire) +96.94% -13.85%
  • Biodexa announces major milestone for its Serenta registrational Phase 3 trial in FAP (GlobeNewswire) -9.35%
  • Result of General Meeting (GlobeNewswire)
  • Biodexa Initiates Support Activities for FAP Patients and Treatment Centers in France (GlobeNewswire)
  • Result of Annual General Meeting (GlobeNewswire)
  • Biodexa Announces Pricing of $3.5 Million Registered Direct Offering & Concurrent Private Placement of Pre-Funded Warrants and Warrants (GlobeNewswire)
  • Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress (GlobeNewswire)
  • Postponement and Re-scheduling of Annual General Meeting (GlobeNewswire)
  • Biodexa issues letter to Shareholders (GlobeNewswire) -8.48%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026S12026-09-110.000--0.2650.00--
2025S22026-03-27-0.005--53.5650.00--
2025S12025-09-12-0.012--778.020.11--
2024S22025-04-11-0.264-0.252-1,8590.11-1
2024S12024-09-26-13.400-8.960-5,1100.110.021
2023S22024-04-19-142-142-14,7880.110.111
2020S12020-09-10-65,868,800--64,321,4000.22--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2015FY-830,139,000-1,244,345,667-859,111,0862.031.66
2016FY-1,099,020,000-884,024,000-1,185,389,9468.6410.73
2017FY-681,691,000-700,806,000-635,513,8459.4310.26
2018FY-352,389,600-578,339,000-468,486,0727.541.41
2019FY-50,270,000--56,152,9270.850.85
2020FY-57,597,284--53,135,6460.47-
2023FY-200-2.840-111,4270.380.49
2024FY-0.524-0.264-5,9290.000.00
2025FY-0.005--0.0050.00-
2026FY-0.000--0.00
2027FY-0.000--0.00
2028FY-0.000--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026FYS2026-03-301000.000.000.00
2026FYR2025-07-26100-0.01-0.01-0.01
2026FYR2025-07-25100-0.01-0.01-0.01
2026FYR2025-07-24100-0.01-0.01-0.01
2026FYR2025-07-23100-0.01-0.01-0.01
2026FYR2025-07-22100-0.01-0.01-0.01
2026FYR2025-07-21100-0.01-0.01-0.01
2026FYR2025-07-20100-0.01-0.01-0.01
2026FYR2025-07-19100-0.01-0.01-0.01
2026FYR2025-07-18100-0.01-0.01-0.01
2026FYR2025-07-17100-0.01-0.01-0.01
2026FYR2025-07-16100-0.01-0.01-0.01
2026FYR2025-07-15100-0.01-0.01-0.01
2026FYR2025-07-14100-0.01-0.01-0.01

Estimate history

EPS, annual-635513844.541-468486071.849-56152926.987-53135646.032-7458547.901-7633095.421-111427.167-5929.049-632.587
Period201720182019202020212022202320242025
EPS, quarterly
Period
Sales, annual0.1920.1990.3980.2310.7950.8610.47400
Period201720182019202020212022202320242025
Sales, quarterly
Period
Shares, annual00000000.0020.056
Period201720182019202020212022202320242025
Shares, quarterly
Period

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.470.860.790.230.400.20
Cost of Goods Sold Incl. D&A0.170.250.320.35-----
Gross Profit-0.17-0.25-0.320.12-----
Selling, General and Administrative Excl. Other12.4510.8911.599.8011.209.8812.4613.5116.35
Research and Development7.005.036.684.745.916.407.7810.0112.48
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-12.63-11.14-11.91-9.68-10.76-9.64-13.79-14.75-17.64
Interest Expense0.030.090.030.050.070.060.040.120.78
Unusual Expense0.170.210.180.100.250.0015.860.000.00
Net Income Before Taxes-5.79-8.55-7.64-9.30-10.46-8.40-30.10-13.93-16.53
Income Taxes0.14-0.14-0.32-0.50-1.02-0.89-1.64-2.28-2.71
Consolidated Net Income-5.93-8.41-7.32-8.80-9.43-7.51-28.45-11.66-13.82
Net Income From Continuing Operations-5.93-8.41-7.32-8.80-9.43-7.51-28.45-11.66-13.82
Net Income-5.93-8.41-7.32-8.80-9.43-7.51-28.45-12.87-18.16
EPS (Recurring)-0.01-0.60-5,808.28-110,569.38-7,488,800.91-7,458,175.00-32,401,784.61-56,150,287.27-468,483,224.29
EPS (Basic, Before Extraordinaries)-53.56-632.59-5,929.05-111,427.17-7,633,095.42-7,458,547.90-53,135,646.03-56,152,926.99-468,486,071.85
EPS (Diluted)-53.56-632.59-5,929.05-111,427.17-7,633,095.42-7,458,547.90-53,135,646.03-56,152,926.99-468,486,071.85
EBITDA-12.45-10.89-11.59-9.33-10.34-9.09-12.22-13.11-16.16
Non-Operating Income (Expense)7.052.894.480.520.631.30-0.410.941.89
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.120.170.270.030.120.10-0.42-0.04-0.04
Price To Sales Ratio---4.474.5221.2869.4131.7424.20
Gross Margin---25.72-----
Operating Margin----2,043.31-1,250.07-1,212.80-5,972.22-3,706.41-8,877.19
Net Margin----1,858.00-1,095.28-944.64-12,327.21-3,232.37-9,142.96
Shares Outstanding932.640.060.000.000.000.000.000.000.00
Market Capitalization1.291.29940.966,338.4912,418,060.48330,854,160.00377,434,816.001,295,608,280.003793408000

Income statement, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S22023S12022S2
Total Revenue0.000.000.000.000.000.100.370.27
Cost of Goods Sold Incl. D&A0.110.070.180.150.170.18--
Gross Profit-0.11-0.07-0.18-0.15-0.17-0.07--
Selling, General and Administrative Excl. Other6.156.305.066.315.174.675.425.90
Research and Development3.923.072.164.192.772.282.783.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.26-6.37-5.24-6.46-5.34-4.74-5.23-5.82
Interest Expense0.010.030.060.010.010.020.030.03
Unusual Expense0.080.100.110.140.000.000.000.24
Net Income Before Taxes-2.42-3.37-5.15-3.29-4.34-4.55-4.76-5.98
Income Taxes0.060.08-0.21-0.16-0.16-0.15-0.36-0.58
Consolidated Net Income-2.48-3.45-4.94-3.13-4.18-4.40-4.40-5.40
Net Income From Continuing Operations-2.48-3.45-4.94-3.13-4.18-4.40-4.40-5.40
Net Income-2.48-3.45-4.94-3.13-4.18-4.40-4.40-5.40
EPS (Recurring)-0.00-59.94-768.92-1,812.32-5,101.08-14,795.28-177,434.15-4,220,596.01
EPS (Basic, Before Extraordinaries)0.00-53.56-778.02-1,858.76-5,109.73-14,787.92-177,429.33-4,358,192.20
EPS (Diluted)0.00-53.56-778.02-1,858.76-5,109.73-14,787.92-177,429.33-4,358,192.20
EBITDA-6.15-6.30-5.06-6.31-5.17-4.57-5.06-5.63
Non-Operating Income (Expense)3.933.120.273.331.010.220.510.12
Stock Option Compensation Expense0.050.070.090.090.18-0.130.02
Price To Sales Ratio----70.6416.902.134.45
Gross Margin------68.67--
Operating Margin------4,559.02-1,424.16-2,144.15
Net Margin------4,230.11-1,197.32-1,989.18
Shares Outstanding932.640.060.020.000.000.000.000.00
Market Capitalization1.2956.25231.33940.962,118.906,338.491,038,378.9912,418,060.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments11.482.097.613.4113.6210.3214.482.9817.86
Short Term Receivables0.300.900.901.781.492.013.523.995.16
Inventories0.000.000.000.000.000.000.000.001.27
Other Current Assets4.968.050.450.450.820.350.200.180.85
Total Current Assets16.7411.038.965.6415.9312.6818.207.1625.14
Net Property, Plant & Equipment0.120.410.731.001.560.742.852.533.42
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Long-Term Note Receivable----0.000.003.48--
Intangible Assets7.597.073.750.010.000.0016.4015.7637.40
Other Assets0.000.000.000.000.000.000.000.600.63
Total Assets24.4518.5113.446.6517.4913.4240.9326.0466.59
Short Term Debt Incl. Current Port. of LT Debt0.080.760.220.190.200.270.550.470.49
Accounts Payable0.000.890.400.410.660.460.960.363.07
Other Current Liabilities8.164.666.481.681.643.356.002.317.75
Total Current Liabilities8.246.307.102.292.494.097.513.1511.31
Long Term Debt0.000.150.380.560.840.087.511.138.37
Provision for Risks Charges0.000.000.000.000.000.070.000.210.00
Other Liabilities0.871.640.000.000.000.000.000.000.00
Total Liabilities9.118.097.482.843.334.2415.024.4819.68
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity15.3410.425.963.8014.169.1825.9121.5546.91
Total Shareholders Equity15.3410.425.963.8014.169.1825.9121.5546.91
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity15.3410.425.963.8014.169.1825.9121.5546.91
Total Liabilities & Stockholders Equity24.4518.5113.446.6517.4913.4240.9326.0466.59
Book Value Per Share15.95177.783,814.8815,130.3256,345.9936,608.145,116.833,887.578,474.21
Tangible Book Value Per Share137.232,005.067,445.762,803,863.3011,501,526.5011,647,516.7532,382,707.61149,310,247.09245,392,788.01
Full-Time Employees111321272018---
Price to Book Ratio1,937.01127.602,124.826,963.96119,262.2865,384.334,310,792.302,551,650.3434.72
Return on Assets-39.17-45.83-87.62-78.14-48.59-104.71-34.82-29.85-22.06
Return on Equity-65.31-89.35-180.19-105.02-64.35-162.17-49.12-40.39-29.15
Return on Invested Capital-54.85-69.26-138.80-216.27-50.07-307.11-38.50-80.09-37.43
Quick Ratio2.031.751.262.476.393.102.422.272.11
Current Ratio2.031.751.262.476.393.102.422.272.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-6.09-8.41-7.32-8.80-9.43-7.51-28.45-12.87-20.04
Depreciation0.180.250.320.350.420.551.561.641.48
Other Funds (Non Cash)-4.92-1.37-3.670.100.09-0.4816.920.631.81
Funds from Operations-10.83-9.53-10.67-8.35-8.92-7.43-9.97-10.60-16.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.612.26-4.77-0.060.25-0.85-2.002.29-1.94
Cash from Operating Activities-9.22-7.27-15.44-8.41-8.67-8.28-11.97-8.31-18.71
Capital Expenditures-1.41-0.91-0.99-0.33-0.08-0.44-0.27-0.41-0.33
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.020.000.000.020.060.180.0012.38
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.00-0.10-0.250.000.00-4.460.00
Other Sources-0.00-0.000.000.003.380.000.00
Cash from Investing Activities-1.38-0.89-0.99-0.42-0.31-0.383.30-4.8712.05
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.3118.1210.6212.960.3012.4312.4918.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.3118.1210.6212.960.3012.4312.4918.000.00
Proceedsfrom Stock Options10.3118.1210.6212.960.3012.4312.4916.590.00
Issuance or Reduction of Debt, Net-0.60-0.590.550.000.00-0.14-7.934.92-7.85
Change in Long Term Debt0.000.000.000.000.000.000.000.00-0.09
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00-
Reduction of Long Term Debt0.000.000.000.000.000.000.000.00-0.09
Net Financing Active Other Cash Flow0.000.000.000.000.000.00-0.241.590.00
Other Financing Activities Uses0.000.000.000.000.000.00-0.290.000.00
Cash from Financing Activities9.5917.2010.9312.730.0812.134.0023.94-7.85
Exchange Rate Effect---0.000.00-0.010.330.190.03
Net Change in Cash-1.019.05-5.503.90-8.893.45-4.3410.95-14.48
Free Cash Flow-9.23-7.27-15.45-8.44-8.74-8.72-12.24-8.70-19.04
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00-0.03

Balance sheet, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Cash & Short Term Investments4.2911.485.532.096.397.61
Short Term Receivables4.590.306.790.903.120.90
Inventories0.000.000.000.000.000.00
Other Current Assets0.004.960.008.050.000.45
Total Current Assets8.8816.7412.3211.039.518.96
Net Property, Plant & Equipment0.030.120.260.410.550.73
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets7.987.597.747.077.593.75
Other Assets0.000.000.000.000.000.00
Total Assets16.8824.4520.3118.5117.6613.44
Short Term Debt Incl. Current Port. of LT Debt0.000.080.690.760.220.22
Accounts Payable0.000.000.004.392.141.58
Other Current Liabilities3.698.162.711.152.055.30
Total Current Liabilities3.698.243.406.304.407.10
Long Term Debt0.000.000.000.150.260.38
Other Liabilities0.440.871.251.641.960.00
Total Liabilities4.139.114.648.096.637.48
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.7615.3415.6710.4211.035.96
Total Shareholders Equity12.7615.3415.6710.4211.035.96
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.7615.3415.6710.4211.035.96
Total Liabilities & Stockholders Equity16.8824.4520.3118.5117.6613.44
Book Value Per Share0.0015.9517.02177.785,078.253,814.88
Tangible Book Value Per Share0.01137.23512.372,005.063,791.487,445.76
Price to Book Ratio1,937.01213.45778.49127.60939.382,124.82
Return on Assets-31.88-39.05-42.45-45.75-61.80-87.63
Return on Equity-41.72-65.11-60.37-89.21-96.62-180.20
Return on Invested Capital-19.42-22.50-31.49-29.56-37.04-69.41
Quick Ratio2.412.033.631.752.161.26
Current Ratio2.412.033.631.752.161.26

Cash flow, quarterly

Currency USD, millions
Metric2026S12025S22025S12024S22024S12023S2
Net Income-2.48-3.61-4.94-3.21-4.18-4.47
Depreciation0.110.070.180.160.170.18
Other Funds (Non Cash)-2.97-1.940.56-2.87-0.840.89
Funds from Operations-5.34-5.49-4.20-5.92-4.85-3.40
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.742.35-0.06-3.72-1.10-0.31
Cash from Operating Activities-6.09-3.13-4.25-9.64-5.96-3.71
Capital Expenditures-0.97-0.44-0.480.08-1.08-0.32
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.020.000.000.000.01
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.00-0.10
Other Sources0.00---0.000.00
Cash from Investing Activities-0.97-0.42-0.480.08-1.08-0.42
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.0010.318.114.745.995.23
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.0010.318.114.745.995.23
Proceedsfrom Stock Options0.0010.318.114.745.995.23
Issuance or Reduction of Debt, Net0.00-0.60-0.180.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.089.677.815.175.875.11
Net Change in Cash-7.146.123.07-4.39-1.160.98
Free Cash Flow-6.09-3.13-4.25-9.66-5.96-3.74

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-611.57K
2026-10-15-0.1M-611.33K
2026-09-30-0.0M-463.56K
2026-09-15-0.0M-463.50K
2026-08-31-0.0M-58.38K
2026-08-14-0.0M-20.75K
2026-07-31-0.0M-56.79K
2026-07-15-0.0M-50.08K
2026-06-30-0.0M-100.76K
2026-06-15-0.0M-91.10K
2026-05-29-0.0M-92.22K
2026-05-15-0.0M-92.87K
2026-04-30-0.0M-57.17K
2026-04-15-0.0M-59.45K
2026-03-31-0.0M-6.37K
2026-03-13-0.0M-15.78K
2026-02-27-0.0M-28.92K
2026-02-13-0.0M-28.20K
2026-01-30-0.0M-27.26K
2026-01-15-0.0M-24.95K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-09SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-14424B3SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-08SEC
2026-10-06424B3SEC
2026-09-30EFFECTEffectiveness filing by commission orderSEC
2026-09-24F-1Registration statement for certain foreign private issuersSEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-15424B3SEC
2026-09-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-15SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-11424B3SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
ARMISTICE CAPITAL, LLC3.28%
StoneX Group Inc.1.21%
GAMMA Investing LLC0.27%
UBS Group AG0.17%
Allied Private Wealth LLC0.11%
SBI Securities Co., Ltd.0.00%
Hilton Head Capital Partners, LLC0.00%
RHUMBLINE ADVISERS0.00%
Caitong International Asset Management Co., Ltd0.00%

Funds

Fund% owned
-

OakChart. BDRX. Cached 15 minutes.

Some panels did not load: insider.